Virtu Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Virtu Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	+10,728	New	+$93.1K	﹤0.01%	1098
2024 Q1	–	Sell	-667	Closed	-$9K	–	1755
2023 Q4	$9K	Buy	+667	New	+$8.99K	﹤0.01%	1418
2022 Q3	–	Sell	-876	Closed	-$59K	–	1980
2022 Q2	$59K	Buy	+876	New	+$80.3K	0.01%	1079
2021 Q3	–	Sell	-1,215	Closed	-$188K	–	1734
2021 Q2	$188K	Sell	1,215 -1,922	-61%	-$279K	0.02%	1021
2021 Q1	$495K	Sell	3,137 -202	-6%	-$42.6K	0.04%	524
2020 Q4	$775K	Buy	+3,339	New	+$774K	0.08%	298
2019 Q4	–	Sell	-684	Closed	-$99K	–	1660
2019 Q3	$99K	Buy	+684	New	+$92.7K	0.01%	1088
2018 Q4	–	Sell	-764	Closed	-$195K	–	1791
2018 Q3	$195K	Buy	+764	New	+$211K	0.01%	1085
2018 Q2	–	Sell	-1,647	Closed	-$332K	–	2266
2018 Q1	$332K	Buy	+1,647	New	+$328K	0.02%	985
2017 Q4	–	Sell	-1,220	Closed	-$201K	–	2699
2017 Q3	$201K	Buy	+1,220	New	+$175K	0.01%	1852

Other funds holding KPTI

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial's KPTI Position: Q2 2026 in Review

Virtu Financial opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 10,728 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #1098 among its holdings. This is a return to the name: Virtu Financial previously reported a position in KPTI as recently as Q4 2023.

Virtu Financial first reported a position in KPTI in Q3 2017 and has held it in 10 quarters since. The position peaked at $775K in Q4 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Virtu Financial held 10,728 shares of Karyopharm Therapeutics worth $105K as of Q2 2026.
Karyopharm Therapeutics was a new Virtu Financial position in Q2 2026.
Karyopharm Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1098 holding.
Virtu Financial first reported a position in Karyopharm Therapeutics in Q3 2017 and has held it in 10 quarters since.
Virtu Financial's Karyopharm Therapeutics position peaked at $775K in Q4 2020.
96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.